Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0027-4.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 70.00K | 70.00K | 70.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 70.00K | 70.00K | 70.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 70.00K | 70.00K | 70.00K |
| SG&A Expenses | 376.00K | 445.80K | 399.80K | 542.30K | 573.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 376.10K | 458.10K | 432.80K | 575.00K | 671.90K |
| Operating Income | -376.10K | -458.10K | -362.80K | -505.00K | -601.90K |
| Income Before Tax | -4.78M | -4.92M | -1.50M | -8.08M | -8.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.78 | -4.92 | -1.50 | -8.08 | -8.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 255.50K | 257.10K | 264.10K | 288.80K | 302.90K |
| Net Income | -4.52M | -4.66M | -1.24M | -7.79M | -7.90M |
| EBIT | -376.10K | -458.10K | -362.80K | -505.00K | -601.90K |
| EBITDA | -- | -110.30K | -92.60K | -328.10K | -589.00K |
| EPS Basic | -0.01 | -0.01 | 0.00 | -0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | -0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.62B | 1.56B | 1.55B | 1.54B | 1.54B |
| Average Diluted Shares Outstanding | 1.62B | 1.56B | 1.55B | 1.54B | 1.54B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |